MarketBeat on MSN2d
Gilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
The S&P500 (SP500) closed in the red on Friday, after the week saw dour economic reports, headlines on U.S. President Donald ...
Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...
Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...
GlobalData on MSN5d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP useLenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback